<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-regains-compliance-with-nasdaqs-publicly-held-shares-re-1165275">Jaguar Health Regains Compliance with Nasdaq&#39;s Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq&#39;s Bid Price Rule</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today provided an update on the status of the Company&#39;s listing on The Nasdaq Stock Market (&quot;Nasdaq&quot;). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel (&quot;Panel&quot;) granting the Company&#39;s request for an extension to demonstrate compliance with the Nasdaq...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-preliminary-discussion-with-fda-to-evaluate-b-1164134">Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)</a>
    </div>

      <div class="me-0 me-md-5">
        Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy Designation Crofelemer has demonstrated meaningful reductions in weekly PS needs in two pediatric MVID pati...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-expands-neonorm-franchise-with-introduction-of-neonorm-1163399">Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health</a>
    </div>

      <div class="me-0 me-md-5">
        Neonorm Dog extends Jaguar&#39;s existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel health Expansion builds on Jaguar&#39;s focus on sustainably derived, plant-based gastrointestinal products for people and animals SAN FRANCISCO, CA / ACCESS Newswire / May 4, 2026 / Ja...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-statistically-significant-results-from-effect-1162317">Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs</a>
    </div>

      <div class="me-0 me-md-5">
        Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its effectiveness trial of crofelemer (FDA conditionally approved Canalevia-CA1) for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The st...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-granted-extension-until-may-15-2026-to-demonstrate-comp-1160319">Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq&#39;s Bid Price Rule; Company Announces Reverse Stock Split</a>
    </div>

      <div class="me-0 me-md-5">
        Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel (the &quot;Pan...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-1159025">Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today announced the voting results of the Company&#39;s Special Meeting of Stockholders held on April 20, 2026 (the &quot;Special Meeting&quot;). Five proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/artificial-intelligence-ai-platforms-could-enhance-jaguar-healths-dev-1156912">Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health&#39;s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs</a>
    </div>

      <div class="me-0 me-md-5">
        Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression modification for intestinal failure (IF) patients with orphan disease designated pediatric microvillus inclu...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Jaguar-Health-Inc-US47010C3007">Jaguar Health, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/reminder-jaguar-health-to-host-investor-webcast-at-8-30-am-eastern-on-1156553">Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates</a>
    </div>

      <div class="me-0 me-md-5">
        Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern Participant Registration &amp; Access Link: Click Here Replay Instructions for Webcast Replay of the webcast on the investor relations section of Jaguar&#39;s website: (click here) About the Jaguar Health ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Jaguar-Health-Inc-US47010C3007/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>